8-K: Contineum Therapeutics Reports Q4 2024 Financial Results and Affirms Clinical Milestones

Contineum Therapeutics announces its fourth-quarter 2024 financial results, highlighting key clinical development milestones and a cash runway projected through 2027.

Summary

• Contineum Therapeutics reported its fourth-quarter 2024 financial results on March 6, 2025.
• The company anticipates topline data from the PIPE-791 Phase 1b PET trial in Q2 2025 and from the PIPE-307 Phase 2 VISTA trial for RRMS in the second half of 2025.
• Contineum expects to sponsor up to six clinical trials during 2025.
• The company plans to initiate Phase 2 proof-of-concept clinical trials in IPF and PrMS in the second half of 2025, pending successful completion of PIPE-791 chronic toxicity studies in the first half of 2025.
• An IND application for CTX-343 is planned for submission to the FDA in the second half of 2025.
• Cash, cash equivalents, and marketable securities totaled $204.8 million as of December 31, 2024.
• The company believes it has sufficient cash to fund operations through 2027.
• Research and development expenses increased by 62% to $13.0 million in Q4 2024 compared to Q4 2023.
• The company anticipates significantly higher research and development expenses for full-year 2025.
• Net loss for the quarter was $14.6 million, compared to $7.8 million in the prior-year quarter.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the strong cash position, upcoming clinical milestones, and ongoing development programs. However, the increased net loss and R&D expenses temper the overall outlook.

Positives

• The company has a strong cash position of $204.8 million, providing a runway through 2027.
• Multiple clinical trial milestones are expected in 2025, including topline data from PIPE-791 and PIPE-307.
• The company is advancing multiple programs in neuroscience, inflammation, and immunology.
• Johnson & Johnson has begun recruiting participants for a Phase 2 trial of PIPE-307/JNJ-89495120 for major depressive disorder.

Negatives

• The company reported a net loss of $14.6 million for the three months ended December 31, 2024, compared to a $7.8 million loss in the prior-year quarter.
• Research and development expenses are expected to be significantly higher in 2025, which could further impact profitability.

Risks

• The company is heavily dependent on the success of PIPE-791 and PIPE-307, which are in early stages of clinical development.
• Clinical trials may not proceed as expected, and results may not be predictive of future outcomes.
• The company relies on third parties to conduct clinical trials and develop PIPE-307 for indications other than RRMS.
• The company has incurred significant operating expenses and expects them to continue to increase.
• The company may be unable to obtain, maintain, and enforce intellectual property protection for its technology and drug candidates.

Future Outlook

Contineum Therapeutics anticipates a pivotal year in 2025 with several important clinical data readouts and trial initiations, and believes it has sufficient cash resources to fund its planned operations through 2027.

Management Comments

• '2025 is shaping up to be a pivotal year, as we have several important clinical data readouts and trial initiations on the horizon,' said Carmine Stengone, CEO, Contineum Therapeutics.
• Stengone continued, 'Our potentially best-in-class/first-in-class LPA1 and M1 receptor antagonists support our vision of seeking better and new therapies for patients that have limited options today.'

Industry Context

Contineum Therapeutics is operating in the competitive biopharmaceutical industry, focusing on neuroscience, inflammation, and immunology. The company's progress with PIPE-791 and PIPE-307 will be closely watched by competitors and potential partners in these therapeutic areas. The collaboration with Johnson & Johnson on PIPE-307 highlights the potential for partnerships in this space.

Comparison to Industry Standards

• Contineum's cash runway through 2027 is a positive sign, as many clinical-stage biopharmaceutical companies face funding challenges.
• The 62% increase in R&D expenses indicates a significant investment in clinical development, which is typical for companies advancing multiple programs.
• Companies like Biohaven and Karuna Therapeutics, which focus on neuroscience, could be considered peers, although they may be at different stages of development or have different therapeutic focuses.
• The Phase 2 trial of PIPE-307/JNJ-89495120 for major depressive disorder being conducted by Johnson & Johnson is a significant milestone, as it expands the potential application of the drug.

Stakeholder Impact

• Shareholders: The announcement provides information on the company's financial performance and clinical development progress, which could influence investment decisions.
• Employees: The company's continued investment in R&D and clinical trials could create opportunities for career advancement and job security.
• Patients: The development of new therapies for NI&I indications could provide new treatment options for patients with unmet needs.
• Partners: The collaboration with Johnson & Johnson highlights the potential for partnerships and collaborations in the biopharmaceutical industry.

Next Steps

• Contineum expects topline data from its PIPE-791 Phase 1b PET trial in the second quarter of 2025.
• The Company anticipates completing its PIPE-791 long-term chronic toxicity studies in the first half of 2025.
• Upon successful completion of the PIPE-791 chronic toxicity studies, Contineum plans to initiate Phase 2 proof-of-concept clinical trials in IPF and PrMS in the second half of 2025.
• The Company anticipates topline data from its PIPE-791 Phase 1b chronic pain trial in early 2026.
• Contineum expects topline data from its PIPE-307 Phase 2 VISTA RRMS trial in the second half of 2025.
• The Company plans to file an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for CTX-343 in the second half of 2025.

Key Dates